4 Post-treatment control or treated controllers? The impact of ART on time to viral rebound in recent seroconverters

4 Post-treatment control or treated controllers? The impact of ART on time to viral rebound in recent seroconverters

Bibliographic Details
Main Authors:	G.E. Martin, M. Gossez, J.P. Williams, W. Stöhr, J. Meyerowitz, E.M. Leitman, G. Ramjee, K. Porter, S. Fidler, J. Frater
Format:	Article
Language:	English
Published:	Elsevier 2016-07-01
Series:	Journal of Virus Eradication
Online Access:	http://www.sciencedirect.com/science/article/pii/S2055664020309493

Similar Items

30 for seroconverting
by: Cristina, James B.
Published: (2002)

Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial.
by: Mary S Campbell, et al.
Published: (2011-03-01)

Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa.
by: Nikos Pantazis, et al.
Published: (2012-01-01)

An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration.
by: Ashley D Olson, et al.
Published: (2014-01-01)

Detection of a single identical cytomegalovirus (CMV) strain in recently seroconverted young women.
by: Suchetha Murthy, et al.
Published: (2011-01-01)

Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters
by: Su-Ru Lin, et al.
Published: (2021-06-01)

Seroconverting blood donors as a resource for characterising and optimising recent infection testing algorithms for incidence estimation.
by: Reshma Kassanjee, et al.
Published: (2011-01-01)

Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers.
by: Fanny Chereau, et al.
Published: (2017-01-01)

The Impact of HCV Infection Duration on HIV Disease Progression and Response to cART amongst HIV Seroconverters in the UK.
by: Jamie Inshaw, et al.
Published: (2015-01-01)

Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint
by: M. Abdel-Mohsen, et al.
Published: (2019-12-01)

Schistosomiasis was not associated with higher HIV-1 plasma or genital set point viral loads among HIV seroconverters from four cohort studies.
by: Aaron F Bochner, et al.
Published: (2019-11-01)

Missed Opportunities for HIV Prevention: Individuals Who HIV Seroconverted Despite Accessing Healthcare
by: Anastos, K., et al.
Published: (2018)

To rebound or not to rebound
by: Bethany A Stahl, et al.
Published: (2017-10-01)

The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy
by: Huntington, S., et al.
Published: (2015)

Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy.
by: Wolfgang Stöhr, et al.
Published: (2013-01-01)

Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection.
by: Elizabeth Hamlyn, et al.
Published: (2012-01-01)

Effect of natural killer cells on viral rebound in HIV-1-infected humanized mice
by: J. Kim, et al.
Published: (2019-12-01)

Protective effect of KIR3DS1 in asymptomatic HIV-1 seroconverters towards AIDS
by: Stalinraja M, et al.
Published: (2012-05-01)

HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound
by: Rasmus Offersen, et al.
Published: (2020-12-01)

Control of rebound virus in HIV-1 infection
by: Kusuwan, Siripattra
Published: (2006)

OA1-2 Enrichment of the HIV reservoir in CD32+ CD4 T cells occurs early and is closely associated with immune checkpoint receptor expression
by: G.E. Martin, et al.
Published: (2017-07-01)

Conditions for post-rebound SHIV control in autologous hematopoietic-stem cell transplantation
by: F. Cardozo, et al.
Published: (2019-12-01)

11 Murine model to predict viral rebound in HIV+ allotransplanted subjects
by: Maria Salgado, et al.
Published: (2017-07-01)

OA4-1 Combined IL-21 and IFNα treatment limits residual inflammation, viral persistence and delays viral rebound in SIV-infected rhesus macaques
by: L. Micci, et al.
Published: (2017-07-01)

Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort.
by: Charlotte H B S van den Berg, et al.
Published: (2011-01-01)

Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort.
by: Patrycja Machnowska, et al.
Published: (2019-01-01)

The risk of AIDS-defining events is decreasing over time in the German HIV-1 Seroconverter Cohort
by: Altmann Mathias, et al.
Published: (2012-04-01)

Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers.
by: Jessica M Conway, et al.
Published: (2019-07-01)

Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya
by: E.K. Maina, et al.
Published: (2020-08-01)

Abnormal T Cell Frequencies, Including Cytomegalovirus-Associated Expansions, Distinguish Seroconverted Subjects at Risk for Type 1 Diabetes
by: Robert Z. Harms, et al.
Published: (2018-10-01)

Assessment of BED HIV-1 incidence assay in seroconverter cohorts: effect of individuals with long-term infection and importance of stable incidence.
by: Janet M McNicholl, et al.
Published: (2011-01-01)

Persistent elevation of Tim-3 and PD-1 on memory T cells despite early ART initiation during primary HIV infection
by: G.E. Martin, et al.
Published: (2019-07-01)

Host genetic factors associated with symptomatic primary HIV infection and disease progression among Argentinean seroconverters.
by: Romina Soledad Coloccini, et al.
Published: (2014-01-01)

Partial control of viral rebound with a Rev-dependent lentiviral vector carrying HSV-tk gene in SIV-infected rhesus macaques
by: Y. Wu, et al.
Published: (2017-12-01)

Cool PDO phase leads to recent rebound in coastal southern California fog
by: Witiw, Michael R., et al.
Published: (2015-12-01)

Differential viral rebound between lymph node and colon after treatment interruption in SHIV-infected rhesus macaques
by: D.C. Hsu, et al.
Published: (2017-12-01)

A phase 2 trial to evaluate the effects of 3BNC117 in addition to antiretroviral therapy on the latent reservoir and viral rebound
by: J. Lorenzi, et al.
Published: (2017-12-01)

Multidrug-resistant HIV viral rebound during early syphilis: a case report
by: Andrea Giacomelli, et al.
Published: (2020-04-01)

Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir.
by: Taina T Immonen, et al.
Published: (2021-06-01)

Arsenic Trioxide Impacts Viral Latency and Delays Viral Rebound after Termination of ART in Chronically SIV‐Infected Macaques
by: Qing Yang, et al.
Published: (2019-07-01)